9.15 am

PET and its real role

L. Kostakoglu

9.45 am

Advanced stage: the old and new match: ABVD

P. Brice

9.45 am

Advanced stage: the old and new match: BEACOPP

P. Borchmann

9.45 am

With the new referee Brentuximab Vedotin

A. Younes

11.30 am

Salvage treatments with Brentuximab Vedotin

C. Moskowitz

12.00 pm

Other new agents

S. Ansell

12.30 pm

The dark side of Hodgkin Lymphoma: elderly patients

A.M. Evens

2.30 pm

PET: the new entry is Follicular Lymphoma

L. Kostakoglu

3.30 pm

Resort

B. Kahl

4.30 pm

How to treat the transformed Lymphoma

J.W. Friedberg

9.00 am

Advanced stage: the addition of biologic agents to the chemo-immunotherapy in front-line

W.H. Wilson

10.00 am

Autologous and allogeneic transplantation:which role?

K. Van Besien

11.45 am

Today, how many PTCL patients are cured?

S.M. Horwitz

12.15 pm

Which is the potential (but close) future in terms of front-line in PTCL?

O.A. O'Connor

12.45 pm

Is there a specific treatment for AITL?

R. Advani

1.15 pm

New agents in PTCL

B. Pro